title: Response of femoral neck to estrogen depletion and parathyroid hormone in aged rats.
abstract: Female Sprague-Dawley rats were ovariectomized (OVX) or sham-operated at 3 months of age and maintained untreated for 1 year after surgery. Baseline control and OVX rats were killed at the beginning of treatment when the rats were 15 months of age and 1 year postovariectomy. The remaining rats were treated with hPTH 1-34 (80 micrograms/kg BW, 5 days/week) or vehicle for 10 weeks. Quantitative bone histomorphometry was performed on undecalcified longitudinal sections of the proximal femur from each rat. Baseline OVX rats exhibited cancellous and cortical osteopenia at the femoral neck as their mean cancellous bone volume and cortical width were significantly decreased compared to the means for baseline control rats. In addition, baseline OVX rats had increased osteoblast and osteoclast surfaces and a greater cancellous bone formation rate than baseline control rats. OVX rats remained osteopenic with no further bone loss from the femoral neck after 10 weeks of vehicle treatment. In contrast, cancellous bone volume and cortical width in OVX rats treated with PTH were increased to the level of vehicle-treated control rats. The hormone restored lost bone in the femoral neck of OVX rats by markedly stimulating both cancellous and cortical bone formation. These histomorphometric findings in concert with recent biomechanical studies of bone strength indicate that the femoral neck of aged OVX rats is a promising sample site for studies of the prevention and treatment of bone loss induced by estrogen depletion.
authors.affiliation: Department of Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville 32610, USA.
authors.forename: M
authors.initials: M
authors.lastname: Li
authors.forename: T J
authors.initials: TJ
authors.lastname: Wronski
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001846:Bone Development / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000188:drug therapy / Q000209:etiology; D004195:Disease Models, Animal; D004967:Estrogens / Q000378:metabolism*; D005260:Female; D005272:Femur Neck / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000209:etiology; D010052:Ovariectomy / Q000009:adverse effects; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013194:Staining and Labeling; D019379:Teriparatide
chemical_list: D004967:Estrogens; D010281:Parathyroid Hormone; D010446:Peptide Fragments; D019379:Teriparatide